ClinicalTrials.gg
CompletedNCT01949805PROUD-PVUpdated Nov 28, 2016

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera

A Phase 3 interventional study of Peg-P-IFN-alpha-2b (AOP2014) and Hydroxyurea in Polycythemia Vera, sponsored by AOP Orphan Pharmaceuticals AG. Completed at 58 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera — 1 open to participants now, 3 under way, 2 of them phase 3. ropeginterferon alfa-2b · Polycythemia Vera.

Enrollment
Largest of 11
257 · median 49
Started
2013
the only one that year
Phase 3
6 of 11
1 open now
Registered
2nd of 11
by date
Lead sponsor
4 of 11
AOP Orphan Pharmaceuticals AG

Among the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, this one has the largest enrollment, is the only one that started in 2013, is one of 6 in phase 3, and was the 2nd registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

1 of the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ropeginterferon alfa-2b

ropeginterferon alfa-2b: first FDA approval 2021 (BESREMI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, or all of them as a file.
02

Study summary

Phase III study to compare the efficacy and safety of the novel monopegylated interferon alpha 2b AOP2014 versus Hydroxyurea (the current licensed therapy for this disease). One year treatment of patients with polycythemia vera. Objective is to demonstrate non-inferiority of AOP2014 vs. HU in terms of disease response rate in both HU naïve and currently treated patients, diagnosed with Polycythemia Vera. Response is measured as normalisation of key lab parameters as well as normalized spleen size.

Read the detailed description

Hydroxyurea is an established first-line treatment option currently approved in several European countries for Polycythemia Vera (PV) patients requiring a cytoreductive therapy (Barbui et al, 2011). Clinical trials have shown that HU is an effective drug for preventing thrombosis in PV compared to phlebotomy (Michiels et al, 1999).

The main concern of a long term treatment with HU is its potential leukaemogenicity: based on the mechanism of action, HU can potentially accelerate the accumulation of mutations in DNA and increase the risk of leukaemic transformation (Dingli et Tefferi, 2006). However, there is currently no clear clinical data to confirm leukaemogenicity of HU in patients with PV (Tefferi, 2012).

Even though IFN-alpha has shown its activity in PV in the 1980s, it is still considered as an experimental treatment in Europe due to pending approval in this indication (Barbui et al, 2011). It induces major or complete molecular remissions in patients with PV accompanied by a reduction in the risk of thrombosis and bleeding - the major determinants of morbidity in this indication (Hasselbalch, 2011). However, only low doses are tolerated and significant adverse effects from long-term use may limit its usefulness.

Pegylated interferons are better tolerated and are the preferred options of treatment in PV patients (Kiladjian et al, 2008) despite the lack of evidences based on well-designed randomized controlled clinical studies.

AOP2014 is a next generation pegylated interferon (Peg-P-IFN-alpha-2b), with the addition of proline in the N-terminal end.

AOP2014 like all interferon suppresses the malignant clone causing PV and subsequently is expected to possibly defer the onset of or avoid long term sequelae of PV. In addition, a reduction in the frequency of phlebotomies should be achieved. The peg-P-IFN-alpha-2b might potentially have a positive impact on reducing the drop-out rate compared to conventional IFNs. It is expected that the reduced frequency of administration of AOP2014 will contribute to higher compliance rates.

The maximum tolerated dose as well as the safety, efficacy and pharmacokinetics of AOP2014 were assessed in a phase I/II study in patients with PV. After 24 evaluable patients had entered the Phase I dose finding part, the MTD was defined at the level of 540 µg administered every two weeks. Another 27 patients were recruited in order to further investigate the drug efficacy and safety in PV. Efficacy results of AOP2014 were promising. By visit 18, 53.0% of the patients had reached complete response (12 evaluable patients). Adverse events were manageable and rarely necessitated treatment discontinuation.

AOP2014 was shown to have a prolonged plasma half-life with a concomitant increase in AUC. This is expected to enhance the therapeutic window of peg-IFN-alpha-2b.

The safety profile of type I interferons alpha is believed to be well characterized after clinical experience for nearly 20 years. Since the dose is carefully titrated to the optimal effective dose no additional risks for the patients are expected. HU, the IMP-comparator in the study, is the standard reference treatment in PV.

This phase III study was designed to compare, for the first time, the efficacy and safety of HU with a pegylated prolin-interferon alpha-2b (AOP2014) in patients with PV. Two populations will be assessed: HU naïve patients and patients currently treated or pre-treated with HU for less than 3 years, not responding to HU treatment (according to criteria in this protocol).

03

Conditions studied

  • Polycythemia Vera

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years or older
  2. Diagnosis of Polycythemia Vera according to the WHO 2008 criteria (Barbui et al, 2011) with the mandatory presence of JAK2V617F mutation as the major disease criterion.
  3. For previously cytoreduction untreated patients - documented need of cytoreductive treatment

    • leukocytosis (WBC>10G/L for two measurements within one week)
  4. For patients currently treated or pre-treated with HU, all of the following criteria:

    • being non responders (as defined by the response criteria for primary endpoint)
    • total HU treatment duration shorter than three years
    • no documented resistance or intolerance as defined by modified Barosi et al, 2009 criteria
  5. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales
  6. Patients with HADS score of 8-10 inclusive on either or both of the subscales may be eligible following psychiatric assessment that excludes clinical significance of the observed symptoms in the context of potential treatment with an interferon alpha
  7. Signed written

Exclusion criteria

Exclusion Criteria:

  1. Any systematic cytoreduction for PV prior study entry with exception of HU for shorter than 3 years (see respective inclusion criterion)
  2. Any to any of the IMPs (pegylated interferon or hydroxyurea) or their
  3. Any systemic exposure to a non-pegylated or pegylated interferon alpha
  4. Documented disease at screening or in the medical history
  5. pulmonary infiltrates, pneumonia, and pneumonitis at screening
  6. Systemic infections, e.g. , , or at screening
  7. Known PV-related thromboembolic complications in the abdominal area (e.g. portal vein thrombosis, Budd-chiari syndrome) and/or splenectomy in the medical history
  8. Any drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent
  9. History or presence of depression requiring treatment with antidepressant
  10. HADS score equal to or above 11 on either or both of the subscales
  11. Any risk of suicide at screening or previous suicide attempts
  12. Any significant morbidity or abnormality which may interfere with the study participation
  13. Pregnancy and breast-feeding females of and males not using effective means of
  14. History of active substance or alcohol abuse within the last year
  15. Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension)
  16. Thyroid dysfunction not adequately controlled
  17. Patients tested positively with TgAb and / or TPOAb at screening
  18. History of major organ transplantation
  19. History of uncontrolled severe seizure disorder
  20. Leukocytopenia at the time of screening
  21. Thrombocytopenia at the time of screening
  22. History of malignant disease, including solid tumours and hematological (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Active comparator
    Hydroxyurea

    Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD

    Drug: Hydroxyurea

  • Experimental
    Peg-P-IFN-alpha-2b (AOP2014)

    Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection

    Drug: Peg-P-IFN-alpha-2b (AOP2014)

Interventions

06

What researchers measure

Primary outcomes

  1. Disease response rate

    Disease response rate is defined as hematocrit \<45% without phlebotomy (at least 3 months since last phlebotomy), platelets \<400 G/L, leukocytes \<10 G/L , and normal spleen size

    Time frame: Month 12

Secondary outcomes

  1. Disease response

    Time frame: at month 3, 6 and 9

  2. JAK2 allelic burden changes

    Time frame: at month 6 and 12

  3. time to response

    will be measured during the study period of 12 months

    Time frame: from inclusion until first response confirmation

  4. duration of response

    from the first documented response on study

    Time frame: during the 12 months of study duration

  5. number of phlebotomies

    Time frame: from inclusion until month 12

  6. blood parameters

    biweekly

    Time frame: from inclusion until month 12

  7. spleen size

    both centrally (blinded assessment) and locally

    Time frame: at month 3, 6, 9 and 12

  8. disease related symptoms

    biweekly

    Time frame: from inclusion until month 12

  9. adverse events

    biweekly

    Time frame: from inclusion until month 12

  10. protocol-specific adverse events of special interest

    biweekly

    Time frame: from inclusion until month 12

07

Study locations

58 sites
  • LKH Graz
    Graz, Austria
  • University Hospital Innsbruck
    Innsbruck, Austria
  • Elisabethinen Hospital Linz
    Linz, Austria
  • Salzburg Regional Hospital
    Salzburg, Austria
  • Hanusch Hospital
    Vienna, Austria
  • Medical University Vienna
    Vienna, Austria
  • Hospital Wels-Grieskirchen
    Wels, Austria
  • Centre du Cancer et D'hematologie
    Brussels, Belgium
  • UZA, Antwerp University Hospital
    Edegem, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Haematolgy, University of Liège
    Liège, Belgium
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi"
    Plovdiv, Bulgaria
  • Specialized Hospital for Active Treatment of Hematological Diseases
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Treatment "Sveta Marina"
    Varna, Bulgaria
  • Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine
    Vratsa, Bulgaria
  • University Hospital Brno
    Brno, Czech Republic
  • University Hospital Hradec Kralove
    Hradec Kralove, Czech Republic
  • Institute of Hematology and Blood Transfusion
    Prague, Czech Republic
  • University Hospital Kralovske Vinohrady
    Prague, Czech Republic
  • University Hospital Motol
    Prague, Czech Republic
  • Institute Paoli-Calmettes
    Marseilles, France
  • Hospital Saint-Louis
    Paris, France
  • Clinical Research Center CIC
    Poitiers, France
  • Aachen University Hospital, Medical Clinic IV
    Aachen, Germany
  • University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III
    Bonn, Germany
  • University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I
    Dresden, Germany
  • St Istvan and St Laszlo Hospital of Budapest
    Budapest, Hungary
  • University of Debrecen
    Debrecen, Hungary
  • Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology
    Gyula, Hungary
  • Kaposi Mor County Teaching Hospital
    Kaposvar, Hungary
  • University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6
    Szeged, Hungary
  • Careggi University Hospital
    Florence, Italy
  • Foundation IRCCS Policlinico San Matteo
    Pavia, Italy
  • Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice
    Katowice, Poland
  • University Hospital in Cracow
    Krakow, Poland
  • Independent Public Teaching Hospital No.1 in Lublin
    Lublin, Poland
  • Fryderyk Chopin Provincial Specialized Hospital
    Rzeszow, Poland
  • Nicolaus Copernicus Municipal Specialist Hospital
    Torun, Poland
  • Institute of Hematology and Transfusion Medicine
    Warsaw, Poland
  • Emergency Clinical County Hospital Brasov
    Brasov, Romania
  • Bucharest University Emergency Hospital
    Bucharest, Romania
  • Coltea Clinical Hospital
    Bucharest, Romania
  • "Prof. Dr. Ion Chiricuta" Institute of Oncology
    Cluj-Napoca, Romania
  • Baranov Republican Hospital
    Petrozavodsk, Russian Federation
  • Samara Kalinin Regional Clinical Hospital
    Samara, Russian Federation
  • First Pavlov State Medical University of St. Petersburg
    St. Petersburg, Russian Federation
  • Komi Republican Oncology Center
    Syktyvkar, Russian Federation
  • Tula Regional Clinical Hospital
    Tula, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, Russian Federation
  • University Hospital with Outpatient Clinic F.D. Roosevelt
    Banska Bystrica, Slovakia
  • Saint Cyril and Metod University Hospital Bratislava
    Bratislava, Slovakia
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center
    Cherkasy, Ukraine
  • Dnipropetrovsk City Multispecialty Clinical Hospital #4
    Dnipropetrovsk, Ukraine
  • National Research Center for Radiation Medicine, Institute of Clinical Radiology
    Kiev, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine
    Lviv, Ukraine
  • O.F. Herbachevskyi Regional Clinical Hospital
    Zhytomyr, Ukraine
08

References and documents

Publications

  • Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0. PubMed 30287855 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2013
First posted
Sep 25, 2013
Start
Sep 2013
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01949805
Lead sponsor
AOP Orphan Pharmaceuticals AG
Collaborators
PharmaEssentia (Co-Sponsor for USA)
Responsible party
Sponsor
First posted
Sep 25, 2013
Start date
Sep 2013
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Nov 28, 2016

Study contacts

Heinz Gisslinger, MD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropeginterferon alfa-2b

Start the discussion